

| Package | Price per Dose | Price | |
|---|---|---|---|
| 360 pills | C$0.90 | C$361.66 C$325.49 Free shipping | |
| 180 pills | C$0.96 | C$191.98 C$172.78 | |
| 120 pills | C$1.02 | C$136.17 C$122.55 | |
| 90 pills | C$1.11 | C$111.61 C$100.45 | |
| 60 pills | C$1.23 | C$82.58 C$74.33 | |
| 30 pills | C$1.25 | C$42.40 C$38.16 | |
| 10 pills | C$1.55 | C$17.84 C$16.05 | |
| 360 pills | C$1.06 | C$428.64 C$385.78 Free shipping | |
| 180 pills | C$1.13 | C$225.47 C$202.92 | |
| 120 pills | C$1.25 | C$165.19 C$148.67 | |
| 90 pills | C$1.37 | C$136.17 C$122.55 | |
| 60 pills | C$1.53 | C$102.68 C$92.41 | |
| 30 pills | C$1.89 | C$62.49 C$56.24 |
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class. It exerts reversible inhibition of cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis, and its primary therapeutic use is the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, and acute musculoskeletal pain.
Diclofenac is available in multiple formulations to optimize onset, duration, and systemic exposure. Oral tablets and capsules provide systemic exposure for generalized pain control; topical diclofenac delivers targeted, localized relief with lower systemic absorption; and specialized forms for ophthalmic or injectable use address specific clinical scenarios. Dosing and formulation selection depend on the site and severity of pain, patient comorbidity, and risk of adverse effects.
Primary indications are centered on chronic inflammatory joint diseases and acute pain states. In adults, diclofenac is commonly employed for symptomatic management of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, where it reduces joint inflammation, stiffness, and pain. It also provides rapid relief for acute musculoskeletal injuries such as strains, sprains, or soft-tissue inflammation, as well as postoperative and dental pain where inflammatory processes contribute to discomfort. Dysmenorrhea is another commonly treated gynecologic indication in suitable formulations.
Secondary or adjunctive uses include management of acute gout flares and inflammatory back pain, especially when rapid analgesia and anti-inflammatory effects are desired. Topical diclofenac formulations target localized musculoskeletal pain, including knee, ankle, or small joint osteoarthritis, or soft-tissue injuries, offering effective relief with reduced systemic exposure. In certain regions, ophthalmic diclofenac preparations are used to control perioperative ocular inflammation and postoperative pain, reflecting a broader but formulation-specific utility profile. Clinical practice balances efficacy with individual GI, renal, hepatic, cardiovascular risk, and potential drug interactions when selecting a therapy plan.
Formulation-specific considerations are important. Oral diclofenac delivers systemic anti-inflammatory effects suitable for widespread joint disease, while topical products are favored when the pain is localized and systemic exposure is a concern. Pediatric use is formulation-dependent and guided by product labeling and age-related safety data. Across indications, treatment goals include minimizing pain, improving function, and preserving tolerability within the patientโs comorbidity context.
Diclofenac achieves its effect primarily through inhibition of the cyclooxygenase (COX) enzymes, COX-1 and COX-2, which catalyze the conversion of arachidonic acid to prostaglandins and other mediators of inflammation. By lowering prostaglandin synthesis, it reduces nociceptor sensitization, vasodilation, and edema at inflamed sites, translating to reduced pain and improved joint function.
In simple terms, the drug dampens the chemical signals that drive swelling and discomfort after tissue injury. Its antipyretic action stems from diminished prostaglandin production in the hypothalamus, helping to lower the bodyโs fever set point during illness. The overall anti-inflammatory effect is dependent on drug concentration at the site of inflammation and on the formulation used, with topical forms achieving local effects with less systemic exposure than oral forms.
Pharmacodynamically, diclofenacโs activity reflects a balance between COX enzyme inhibition and individual patient factors such as age, renal function, and concomitant medications. Analgesia from diclofenac often exceeds simple pain relief in acute tissue injury due to its concurrent anti-inflammatory actions, whereas chronic conditions rely on ongoing suppression of inflammatory mediators to maintain function and mobility.
Gastrointestinal effects are among the most frequently reported adverse events with NSAIDs: dyspepsia, abdominal pain, gastritis, and, less commonly, peptic ulcers or GI bleeding. The risk increases with age, a history of ulcer disease, prior NSAID intolerance, high-dose regimens, and coadministration of anticoagulants or corticosteroids. GI safety strategies include using the lowest effective dose for the shortest duration and, when indicated, co-prescribing gastroprotective agents in high-risk individuals.
Cardiovascular and renal safety concerns warrant careful assessment before initiating therapy. Diclofenac may elevate blood pressure, promote fluid retention, and, at higher exposures or prolonged use, contribute to cardiovascular events in susceptible patients. Renal impairment, impaired renal perfusion, or dehydration can worsen nephrotoxicity; dose adjustments or avoidance may be necessary in at-risk populations. Hepatic monitoring is advised if liver enzymes are abnormal or if concomitant hepatically metabolized drugs are used.
Common nonserious adverse effects include nausea, heartburn, headache, dizziness, and skin reactions. Hypersensitivity and anaphylactoid reactions, though uncommon, require immediate discontinuation. Serious, though rare, cutaneous adverse reactions and NSAID-exacerbated respiratory disease can occur. Diclofenac should be avoided in the third trimester of pregnancy and used with caution in women who are breastfeeding, reflecting potential fetal and neonatal risks. Clinicians should review concomitant therapies for interactions with anticoagulants, antiplatelet agents, ACE inhibitors, diuretics, and other NSAIDs, to minimize risk and optimize safety.
Orally administered diclofenac is rapidly absorbed, with peak plasma concentrations typically reaching within 1โ2 hours for standard salts; the potassium salt formulation often yields a faster onset than the sodium salt. It is highly protein-bound and undergoes hepatic metabolism to hydroxylated and conjugated metabolites, with renal and biliary excretion of the metabolites and parent compound. The elimination half-life is usually short, but clinical analgesia can persist beyond plasma decline depending on formulation and tissue distribution.
Formulations include immediate-release and delayed-release oral tablets or capsules, extended-release forms, topical diclofenac gels or solutions, transdermal patches, and ophthalmic solutions. Topical products provide targeted relief for localized joint or soft-tissue pain with lower systemic exposure, which may translate to a distinct safety profile. Dosing strategies are formulation-specific and tailored to the location and severity of pain, patient age, and risk factors. In all cases, clinicians aim to use the minimum effective dose for the shortest feasible duration and to monitor for adverse effects and drug interactions.
14โ21 days. Free from C$287.05 .
5โ9 days. C$43.06
โ10% when paying with cryptocurrency.
โ10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
